Harrow, a prominent U.S. eyecare pharmaceutical company, is pleased to announce the addition of Mark Mannebach, Ph.D., R.Ph. to their team as the new Head of Regulatory Affairs and Pharmacovigilance. With an impressive 30-year career in the pharmaceutical industry, much of which was focused on ophthalmology, Dr. Mannebach brings a wealth of expertise to the role, including leadership roles in regulatory affairs, quality assurance, program management, and pharmaceutical product development. Harrow looks forward to the guidance and strategic insights Dr. Mannebach will provide related to new and existing products.
Harrow is thrilled to welcome Dr. Mannebach to the team, bringing decades of regulatory and clinical expertise and leadership in ophthalmology. Mark L. Baum, Chairman and Chief Executive Officer of Harrow, is confident that Mannebach’s industry knowledge, experience with U.S. regulatory agencies, and proficiency in developing and implementing effective regulatory processes to comply with FDA guidelines and applicable federal laws, will be a great asset to the company as they launch IHEEZO™, leverage their recent product acquisitions, and pursue new product acquisition and development opportunities.
Dr. Mannebach is thrilled to be joining the Harrow management team and contributing to the transformational changes that are underway. With his expertise and experience, he is eager to strengthen Harrow’s regulatory and compliance commitments and foster positive relationships with the FDA to ensure that Harrow upholds the highest standards of ophthalmic care and provides eyecare professionals and their patients with access to Harrow’s cutting-edge pharmaceutical products.
Dr. Mannebach has an impressive career in regulatory affairs, having held a variety of leadership roles at some of the biggest names in the pharmaceutical industry. From his position as Vice President of Global Regulatory Affairs at Mallinckrodt Pharmaceuticals to his current role as a regulatory and compliance consultant to various start-up biotech companies, Dr. Mannebach has consistently proven himself as a knowledgeable and reliable leader. His impressive experience includes positions at Sanofi, Pharmacia, Baxter, and Pfizer.
Harrow, a leading U.S. eyecare pharmaceutical company, is revolutionizing the industry with its innovative ophthalmic prescription therapies that are designed to be both accessible and affordable. Harrow holds the commercial rights to ten FDA-approved ophthalmic products and operates ImprimisRx, a mail-order pharmacy licensed to ship prescription medications in all 50 states. In addition, Harrow also maintains non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. and holds royalty rights in four late-stage drug candidates being developed by the two subsidiaries. Harrow is dedicated to providing the best possible care for its customers and is working hard to ensure that its products are available to all.